EUCTR2013-003683-31-PT进行中（未招募）不适用
An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Key Inclusion Criteria:
- •- FEV1 > 40% predicted
- •- patients who completed CQGE031B2201 study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Key Exclusion Criteria:
- •- life-threatening asthma attack, intubation, respiratory arrest during or after completion of CQGE031B2201 study
- •- new malignancy
- •- ongoing SAE from CQGE031B2201 that was assessed as related to study drug
- •- patient experienced platelets drop to < 75,000/uL
- •- patient experienced one unexpected grade 4 or two unexpected grade 3 hypersensitivity reactions
- •- patient is pregnant
研究者
相似试验
招募中
2 期
A long term clinical study to determine safety, tolerability and efficacy of drug called Evenamide which is taken orally, by patients with treatment resistant schizophrenia having inadequate benefit from their current antipsychotic medication.CTRI/2020/09/027959ewron Pharmaceuticals SpA
进行中（未招募）
不适用
ong-term safety study of QGE031 in patients with allergic asthma who completed study CQGE031B2201AsthmaEUCTR2013-003683-31-SKovartis Pharma Services AG300
进行中（未招募）
1 期
An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication.EUCTR2020-000439-32-ITEWRON PHARMACEUTICALS SPA150
已完成
2 期
A long-term clinical study using Evenamide (orally taken new drug without masking its strength) to determine its safety, tolerability and efficacy in patients with treatment resistant schizophrenia, not befitting adequately from their current antipsychotic medicatioSchizophreniaSLCTR/2020/024Dr Ravi Anand/Newron Pharmaceuticals S.p.A
进行中（未招募）
1 期
ong-term safety study of QGE031 in patients with allergic asthma who completed study CQGE031B2201AsthmaMedDRA version: 18.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-003683-31-PLovartis Pharma Services AG300